Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.

ABSTRACT:

Background

Nemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus.

Objective

This study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of nemolizumab with the improvement in clinical indices.

Methods and materials

PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) published from inception to August 2021.

Results

A total of 14 cohorts of participants from six randomized controlled studies were included in the meta-analysis. Nemolizumab significantly reduced the pruritus VAS (WMD = -18.86, 95% CI: -27.57 to -10.15, p < 0.001; I² = 56.2%, p_{heterogeneity} = 0.005) and

SUBMITTER: Liang J 

PROVIDER: S-EPMC9086972 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature